InMed Net Debt vs Current Deferred Revenue Analysis
| INM Stock | USD 4.30 0.23 5.08% |
InMed Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating InMed Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether InMed Pharmaceuticals is a good investment. Please check the relationship between InMed Pharmaceuticals Net Debt and its Current Deferred Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
Net Debt vs Current Deferred Revenue
Net Debt vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of InMed Pharmaceuticals Net Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have very week relationship.
The correlation between InMed Pharmaceuticals' Net Debt and Current Deferred Revenue is 0.23. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of InMed Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of InMed Pharmaceuticals' Net Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of InMed Pharmaceuticals are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Net Debt i.e., InMed Pharmaceuticals' Net Debt and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.23 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from InMed Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into InMed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.At this time, InMed Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 29th of November 2024, Tax Provision is likely to grow to 7,407, though Enterprise Value Multiple is likely to grow to (2.02).
| 2021 | 2023 | 2024 (projected) | Interest Expense | 96.1K | 86.5K | 153.3K | Depreciation And Amortization | 511.8K | 604.5K | 634.7K |
InMed Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
InMed Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
InMed Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 7.5M | 9.8M | 12.8M | 14.1M | 11.8M | 12.4M | |
| Total Current Liabilities | 1.7M | 2.2M | 3.3M | 2.0M | 2.0M | 1.1M | |
| Total Stockholder Equity | 5.6M | 7.4M | 9.1M | 12.1M | 9.2M | 9.7M | |
| Property Plant And Equipment Net | 402.6K | 326.6K | 904.3K | 723.4K | 1.2M | 1.3M | |
| Net Debt | (5.5M) | (7.1M) | (5.4M) | (8.5M) | (5.6M) | (5.3M) | |
| Retained Earnings | (56.0M) | (74.9M) | (93.5M) | (101.4M) | (109.1M) | (103.6M) | |
| Accounts Payable | 959.2K | 775.1K | 1.2M | 544.2K | 626.2K | 615.9K | |
| Cash | 5.8M | 7.4M | 6.2M | 8.9M | 6.6M | 3.4M | |
| Non Current Assets Total | 1.2M | 1.4M | 3.2M | 2.8M | 3.1M | 3.3M | |
| Cash And Short Term Investments | 5.8M | 7.4M | 6.2M | 8.9M | 6.6M | 3.9M | |
| Net Receivables | 45.2K | 11.9K | 88.0K | 260.4K | 352.8K | 370.5K | |
| Common Stock Shares Outstanding | 208.8K | 270K | 560.8K | 2.4M | 7.6M | 8.0M | |
| Short Term Investments | 42.3K | 46.5K | 44.8K | 44.4M | 43.1M | 45.2M | |
| Liabilities And Stockholders Equity | 7.5M | 9.8M | 12.8M | 14.1M | 11.8M | 12.4M | |
| Non Current Liabilities Total | 247.5K | 189.3K | 389.5K | 16.0K | 644.9K | 677.1K | |
| Inventory | (919.56) | (955.8M) | 2.5M | 1.6M | 1.2M | 1.3M | |
| Other Current Assets | 418.9K | 956.8K | 842.0K | (8.9B) | 477.7K | 501.6K | |
| Other Stockholder Equity | (59.5M) | 21.5M | 31.7M | 35.7M | 35.4M | 37.1M | |
| Total Liab | 1.9M | 2.4M | 3.7M | 2.0M | 2.6M | 2.7M | |
| Total Current Assets | 6.3M | 8.4M | 9.6M | 11.3M | 8.7M | 9.1M | |
| Accumulated Other Comprehensive Income | 59.6M | 63.4M | 70.8M | 128.6K | 147.9K | 140.5K | |
| Intangible Assets | 799.3K | 1.1M | 2.1M | 1.9M | 1.8M | 1.9M | |
| Common Stock | 50.2M | 60.6M | 70.7M | 77.6M | 82.8M | 53.5M | |
| Net Tangible Assets | 6.5M | 6.3M | 7.0M | 10.1M | 9.1M | 9.1M | |
| Net Invested Capital | 5.6M | 7.4M | 9.1M | 12.1M | 9.2M | 8.4M | |
| Net Working Capital | 4.6M | 6.2M | 6.3M | 9.3M | 6.7M | 7.1M | |
| Property Plant Equipment | 549.9K | 326.6K | 904.3K | 723.4K | 831.9K | 873.5K | |
| Capital Stock | 50.2M | 60.6M | 70.7M | 77.6M | 82.8M | 72.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 230.4 | Revenue Per Share 0.603 | Quarterly Revenue Growth (0.45) | Return On Assets (0.39) | Return On Equity (0.72) |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.